Morningstar
•
Oct 29, 2026
Merck & Co., Inc.: Merck Earnings: Modest 2027 Expectations, but Growing Pipeline Potential
Summary
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Market Update: CB, F, FLEX, ISRG, TSCO, VZ
Oct 30, 2026
•
VZ, F, FLEX, TSCO, ISRG, CB
Analyst Report: Verizon Communications Inc
Oct 30, 2026
•
VZ
Analyst Report: ExxonMobil Holdings Corporation
Oct 30, 2026
•
XOM
Analyst Report: Chevron Corporation
Oct 30, 2026
•
CVX
Analyst Report: Eli Lilly & Co
Oct 30, 2026
•
LLY
Analyst Profile
Karen Andersen
Sector Strategist
Karen Andersen, CFA, is a healthcare strategist for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She is responsible for biotechnology research.Before joining Morningstar in 2005, Andersen received a master’s degree in business administration from Rice University, where she served as senior healthcare analyst for the M.A. Wright Fund and earned the distinction of Jones Scholar. She has scientific research experience in both academia (at Rice University and the University of Queensland in Australia) and industry (at Lexicon Genetics and a subsidiary of Genzyme).Andersen also holds a bachelor’s degree in biochemistry from Rice University, where she graduated magna cum laude. She is a member of Phi Beta Kappa and holds the Chartered Financial Analyst® designation. She ranked first in the biotechnology industry, and had the highest score overall, in The Wall Street Journal’s annual “Best on the Street” analysts survey in 2013, the last year the survey was conducted.
